Drugs / SGN-CD70A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02216890 | Aug 2014 → Feb 2017 | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, renal cell carcinoma | Seagen Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGN-CD70A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02216890 ↗ |
| Route | Intravenous | “Given intravenously” NCT02216890 ↗ |